Medication use during pregnancy and lactation: An urgent call for public health action

Journal of Women's Health

Volumn 14, Issue 2, 2005, Pages 104-109

  Lagoy, Caroline T ^a   Joshi, Namita ^a   Cragan, Janet D ^a,b   Rasmussen, Sonja A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; HERBACEOUS AGENT; NON PRESCRIPTION DRUG;

ACCESS TO INFORMATION; ARTICLE; ASTHMA; BREAST FEEDING; DATA BASE; DIET SUPPLEMENTATION; DRUG EXPOSURE; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ECLAMPSIA; EPILEPSY; FEMALE; FREQUENCY ANALYSIS; GESTATIONAL AGE; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH PRACTITIONER; HUMAN; INFORMATION PROCESSING; LACTATION; LOW BIRTH WEIGHT; MATERNAL WELFARE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL RESEARCH; MENTAL DISEASE; PATIENT COUNSELING; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; SOCIAL SUPPORT; SUICIDE ATTEMPT; TERATOGENICITY; UNITED STATES;

ADULT; ATTITUDE TO HEALTH; BREAST FEEDING; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); FEMALE; HEALTH EDUCATION; HEALTH PROMOTION; HUMANS; LACTATION; MATERNAL WELFARE; MOTHERS; PHARMACEUTICAL PREPARATIONS; PREGNANCY; UNITED STATES; WOMEN'S HEALTH;

EID: 17644398728     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2005.14.104     Document Type: Article

References (46)

1. Lanz W. Thalidomide and congenital abnormalities. Lancet 1962;1:45.
2. Scialli AR, Buelke-Sam JL, Chambers CD, et al. Communicating risks during pregnancy: A workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res Part A Clin Mol Teratol 2004;70:7.
3. Mitchell AA. Special considerations in studies of drug-induced birth defects. In: Strom B, ed. Pharmacoepidemiology. Hoboken, NJ: John Wiley & Sons, 2000.
4. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002;287:337.
5. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398.
6. Tsui B, Dennehy CE, Tsourounis C. A survey of dietary supplement use during pregnancy at an academic medical center. Am J Obstet Gynecol 2001; 185:433.
7. Della-Guistina K, Chow G. Medications in pregnancy and lactation. Emerg Med Clin North Am 2003;21:585.
8. Ito S, Lieu M, Chan W, Koren G. Continuing drug therapy while breastfeeding. Part 1. Common misconceptions of patients. Can Fam Phys 1999;45:897.
9. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transplant 2002;121.
10. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24, 46.
11. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002;100:465.
12. Hatton RC, Doering PL, Frias JL. Physicians' sources of information about teratogenic effects of drugs. Drug Inf J 1982;16:148.
13. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: Fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001;26:44.
14. Polifka JE, Friedman JM. Developmental toxicity of ribavirin/IFNalpha combination therapy: Is the label more dangerous than the drugs? Birth Defects Res Part A Clin Mol Teratol 2003;67:8.
15. Conover E, Buehler BA. Use of herbal agents by breastfeeding women may affect infants. Pediatr Ann 2004;33:235.
16. Ryan AS, Wenjun Z, Acosta A. Breastfeeding continues to increase into the new millennium. Pediatrics 2002;110:1103.
17. Allen VM, Joseph KS, Murphy KE, Magee LA, Ohlsson A. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: A population-based study. BMC Pregnancy Childbirth 2004;4:17.
18. Blaiss MS. Managing asthma during pregnancy. The whys and hows of aggressive control. Postgrad Med 2004;115:55, 61.
19. Guy ES, Kirumaki A, Hanania NA. Acute asthma in pregnancy. Crit Care Clin 2004;20:731.
20. Little BB. Pharmacokinetics during pregnancy: Evidence-based maternal dose formulation. Obstet Gynecol 1999;93:858.
21. Riviello JJ. Classification of seizures and epilepsy. Curr Neurol Neurosci Rep 2003;3:325.
22. Valproic acid and spina bifida: A preliminary report - France. MMWR 1982;31:565.
23. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: A 6-year experience. Arch Neurol 2004;61:673.
24. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: Comparison of two recent guidelines. Lancet Neurol 2004;3:618.
25. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776.
26. Ito S, Koren G, Einarson TR. Maternal noncompliance with antibiotics during breastfeeding. Ann Pharmacother 1993;27:40.
27. Kennedy DL, Uhl K, Kweder SL. Pregnancy exposure registries. Drug Safety 2004;27:215.
28. Shields KE, Wiholm BE, Hostelley LS, et al. Monitoring outcomes of pregnancy following drug exposure: A company-based pregnancy registry program. Drug Safety 2004;27:353.
29. Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment. Am J Obstet Gynecol 2000;182:159.
30. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999;60:356.
31. Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 1981;245:2311.
32. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep 2001;116(Suppl 1):32.
33. Hennekens C, Buring J. Epidemiology in medicine. Boston: Little, Brown and Company, 1987.
34. Mitchell AA. Systematic identification of drugs that cause birth defects - A new opportunity. N Engl J Med 2003;349:2556.
35. Clinical Teratology Website. University of Washington. depts.washington.edu/~terisweb/teris/ Accessed October 20, 2004.
36. REPROTOX, An Online Reproductive Toxicology Resource. Reproductive Toxicology Center. reprotox.org/ Accessed October 20, 2004.
37. Uhl K, Kennedy DL, Kweder SL. Information on medication use in pregnancy. Am Fam Phys 2003;67:2476.
38. REPRORISK. Micromedex, Inc. www.micromedex.com/products/reprorisk/ Accessed November 23, 2004.
39. Shepard TH. Catalog of teratogenic agents. Baltimore, MD: Johns Hopkins University Press, 2001.
40. Friedman JM. Teratogenic effects of drugs: A resource for clinicians: TERIS. Baltimore, MD: Johns Hopkins University Press, 1995.
41. Scialli AR. Reproductive effects of chemical, physical, and biologic agents: REPROTOX. Baltimore, MD: Johns Hopkins University Press, 1995.
42. Briggs GG, Freeman RK, Yaffe SJ. A reference guide to fetal and neonatal risk: Drugs in pregnancy and lactation, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
43. Rieder MJ, Morrison C. A survey of information provided by North American Teratogenic Information Services. Reprod Toxicol 1994;8:425.
44. Felix R, Jones K, Johnson K, CA M, Chambers CD. Postmarketing surveillance for drug safety in pregnancy: The Organization of Teratology Information Services Project. Birth Defects Research Part A: Clinical and Molecular Teratology. 2004;70:944.
45. Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 2001;95:127.
46. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160:1190.